tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of David Nierengarten, 291 are a BUY (83.14%), 57 are a HOLD (16.29%), 2 are a SELL (0.57%).
Analyst David Nierengarten, currently employed at WEDBUSH, carries an average stock price target met ratio of 43.51% that have a potential upside of 44.58% achieved within 204 days.
David Nierengarten’s has documented 776 price targets and ratings displayed on 60 stocks. The coverage is on Healthcare, Communication Services, Technology sectors.
Most recent stock forecast was given on IMNM, Immunome at 20-Mar-2025.
Analyst best performing recommendations are on SRRK (SCHOLAR ROCK HOLDING CORP).
The best stock recommendation documented was for SRRK (SCHOLAR ROCK HOLDING CORP) at 6/18/2018. The price target of $25 was fulfilled within 1 day with a profit of $3.57 (16.66%) receiving and performance score of 166.59.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$42
$23.49 (126.90%)
$36
1 months ago
(05-Mar-2025)
7/13 (53.85%)
$25.3 (151.50%)
545
Hold
$22
$3.49 (18.85%)
$19
1 months 1 days ago
(04-Mar-2025)
2/8 (25%)
$6.75 (44.26%)
37
Buy
$40
$21.49 (116.10%)
$42
1 months 29 days ago
(07-Feb-2025)
11/18 (61.11%)
$25.42 (174.35%)
108
Hold
$18
$-0.51 (-2.76%)
$33
3 months 23 days ago
(13-Dec-2024)
5/11 (45.45%)
$2.41 (15.46%)
109
Buy
$36
$17.49 (94.49%)
$90
3 months 24 days ago
(12-Dec-2024)
2/9 (22.22%)
$20.98 (139.68%)
229
Which stock is David Nierengarten is most bullish on?
Which stock is David Nierengarten is most reserved on?
What Year was the first public recommendation made by David Nierengarten?
